dc.contributor.author | Martin-Galiano, Antonio Javier | |
dc.contributor.author | Díez-Fuertes, Francisco | |
dc.contributor.author | McConnell, Michael J | |
dc.contributor.author | Lopez, Daniel | |
dc.date.accessioned | 2022-05-09T13:00:50Z | |
dc.date.available | 2022-05-09T13:00:50Z | |
dc.date.issued | 2021-11 | |
dc.identifier.citation | Front Immunol. 2021 Nov 25;12:732693. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/14350 | |
dc.description.abstract | The effect of emerging SARS-CoV-2 variants on vaccine efficacy is of critical importance. In this study, the potential impact of mutations that facilitate escape from the cytotoxic cellular immune response in these new virus variants for the 551 most abundant HLA class I alleles was analyzed. Computational prediction showed that most of these alleles, that cover >90% of the population, contain enough epitopes without escape mutations in the principal SARS-CoV-2 variants. These data suggest that the cytotoxic cellular immune protection elicited by vaccination is not greatly affected by emerging SARS-CoV-2 variants. | es_ES |
dc.description.sponsorship | This research was supported by grants from COV20_00679 (MPY 222-20), to MM, MPY 509/19 to AM-G, and MPY 388/18 to DL of “Acción Estratégica en Salud” from the ISCIII. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | HLA | es_ES |
dc.subject | SARS-CoV-2 | es_ES |
dc.subject | T cell epitope | es_ES |
dc.subject | Epidemic | es_ES |
dc.subject | Escape mutant | es_ES |
dc.subject | Vaccine | es_ES |
dc.title | Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 34899692 | es_ES |
dc.format.volume | 12 | es_ES |
dc.format.page | 732693 | es_ES |
dc.identifier.doi | 10.3389/fimmu.2021.732693 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1664-3224 | es_ES |
dc.relation.publisherversion | https://doi.org/10.3389/fimmu.2021.732693 | es_ES |
dc.identifier.journal | Frontiers in Immunology | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/MPY222/20 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/MPY388/18 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/MPY509/19 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/COV20_00679 | es_ES |